Gail Ferstandig Arnold, Ph.D.

Research Interests and Activities:

• Engaged in greater than 20 years leading a research group at Rutgers focused on the development of AIDS vaccine components using combinatorial libraries and immunoselection approaches
• Working with the Founding Director of IQB to:
  • Create next-generation educational programs to catapult students, postdoctoral fellows, staff, faculty, clinicians, and colleagues in industry toward more powerful ways of addressing today’s grand challenges in biology and medicine
    • Boot Camps
    • Crash Courses
    • New courses and mini-courses in the Rutgers curriculum
    • Seminars
  • Develop initiatives to bring students, postdoctoral fellows, staff, faculty, clinicians, and colleagues in industry together to promote collaborative, interdisciplinary research efforts
    •  Research Working Groups
    •  Promotion of collaborative connections through a broad network of contacts
•  Working with the Graduate Program Director of Quantitative Biomedicine to:
  • Provide one-on-one guidance to Quantitative Biomedicine Ph.D. students and Joint Ph.D. students to optimize their coursework and research efforts
  • Offer career development and resources for additional career development
  • Serve as the faculty liaison for the Joint Quantitative Biomedicine GSO

 Selected Publications:

1. Yi, G., M. Lapelosa, R. Bradley, T. Mariano, D.E. Dietz, S. Hughes, T. Wrin, C.J. Petropoulos, E. Gallicchio, R.M. Levy, E. Arnold, and G.F. Arnold. 2013. Presentation of the HIV-1 gp41 MPER epitopes recognized by mAbs 2F5 and 4E10 on human rhinovirus both lead to measurable neutralizing responses. PLoS ONE 8(9): e72205. doi:10.1371/journal.pone.0072205.
2. Lapelosa, M., G. Ferstandig Arnold, E. Gallicchio, E. Arnold, and R.M. Levy. 2010. Antigenic characteristics of rhinovirus chimeras designed in silico for enhanced presentation of HIV-1 gp41 epitopes. J. Mol. Biol. 397:752-766, doi:10.1016/j.jmb.2010.01.064; Epub 2010 Feb 4.
3. Arnold, G.F., P.K. Velasco, X. Ma, S.C. Geisler, T. Wrin, C.J. Petropoulos, Y. Tian, J.W. Taylor, H. Katinger, and E. Arnold. 2009. Broad neutralization of HIV-1 elicited from human rhinoviruses that display HIV-1 gp41 ELDKWA. J. Virol. 83:5087-5100, doi:10.1128/JVI.00184-09.
4. Lapelosa, M., E. Gallicchio, G. Ferstandig Arnold, E. Arnold, and R.M. Levy. 2009. In silico vaccine design based on molecular simulations of rhinovirus chimeras presenting HIV-1 gp41 epitopes. J. Mol. Biol. 385:675-691, http://dx.doi:1016/j.jmb.2008.10.089; Epub
5. Maeda, K., D. Das, H. Ogata-Aoki, H. Nakata, T. Miyakawa, Y. Tojo, R. Norman, Y. Takaoka, T. Miyakawa, Y. Tojo, R. Norman, Y. Takaoka, J. Ding, G.F. Arnold, E. Arnold, and H. Mitsuya. 2006. Structural and molecular interactions of CCR5 inhibitors with CCR5. J. Biol. Chem. 281:12688-12698. 2008 Nov 8; NIHMS92574.
6. Tian, Y., C.V. Ramesh, X. Ma, S. Naqvi, T. Patel, T. Cenizal, M. Tiscione, K. Diaz, T. Crea, E.Arnold, G.F. Arnold, and J.W. Taylor. 2002. Structure-affinity relationships in the gp41 ELDKWA epitope for the HIV-1 neutralizing monoclonal antibody 2F5: effects of side-chain and backbone modifications and conformational constraints. J. Peptide Res. 59:264-276.
7. Ding, J., A.D. Smith, S.C. Geisler, G.F. Arnold, and E. Arnold. 2002. Crystal structure of a human rhinovirus that displays part of HIV-1 V3 loop and induces neutralizing antibodies against HIV-1. Structure 10:999-1011.
8. Zhang, A., S.C. Geisler, A.D. Smith, D.A. Resnick, M.L. Li, C.-Y. Wang, D.J. Looney, E. Arnold, and G.F. Arnold. 1998. A disulfide-bound HIV-1 V3 loop sequence on the surface of human rhinovirus 14 induces a neutralizing response against HIV-1. Biol. Chem. 380:365-374.
9. Smith, A.D., S.C. Geisler, A.A. Chen, D.A. Resnick, B.M. Roy, P. Lewi, E. Arnold, and G.F. Arnold. 1998. Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1. J. Virol. 72:651-659.
10. Arnold, G.F., D.A. Resnick, A.D. Smith, S.C. Geisler, A.K. Holmes, E. Arnold. 1996. Chimeric rhinoviruses as tools for vaccine development and characterization of protein epitopes. Intervirology 39:72-78.
11. Resnick, D.A., A.D. Smith, S.C. Geisler, A. Zhang, E. Arnold, G.F. Arnold. 1995. Chimeras from a human rhinovirus 14:human immunodeficiency virus type 1 V3 loop seroprevalence library induce neutralizing responses against HIV-1. J. Virol. 69:2406-2411.
12. Resnick, D.A., A.D. Smith, A. Zhang, S.C. Geisler, E. Arnold, and G.F. Arnold. 1994. Libraries of human rhinovirus-based HIV vaccines generated using random systematic mutagenesis. AIDS Res. and Hum. Retroviruses 10:S47-S52.
13. Arnold, G.F., D.A. Resnick, Y. Li, A. Zhang, A.D. Smith, S.C. Geisler, A. Jacobo-Molina, W.M.Lee, R.G. Webster, and E. Arnold. 1994. Design and construction of rhinovirus chimeras displaying immunogens from polio, influenza, and human immunodeficiency viruses. Virology 198:703-708.
14. Zhang, A., R.G. Nanni, T. Li, G.F. Arnold, D.A. Oren, A. Jacobo-Molina, R.L. Williams, G. Kamer, D.A. Rubenstein, Y. Li, E. Rozhon, S. Cox, P. Buontempo, J. O'Connell, J. Schwartz, G. Miller, B. Bauer, R. Versace, P. Pinto, A. Ganguly, V. Girijavallabhan, and E. Arnold. 1993. Structure determination of antiviral compound 38057 complexed with human rhinovirus 14 . J. Mol. Biol. 230:857-867.
15. Arnold, E., G.F. Arnold. 1990. Virus structure and the AIDS problem: strategies for antiviral design based on structure. "The Use of X-ray Crystallography in the Design of Antiviral Agents", W.G. Laver and G. Air, eds., Academic Press, New York. pp. 283-295.